Solid Tumors | Norton Healthcare

Indication: Solid Tumors

A Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody™ Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors (PROCLAIM-CX-072)

Metastatic or Locally Advanced Unresectable

Drug Study

Principal Investigator: Jaspreet Grewal, M.D.
Norton Cancer Institute

Sponsor: CytomX Therapeutics, Inc.

Learn more at

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.